Novo Nordisk’s Obesity Pill Results Send Shares to Record
- Volunteers taking amycretin lost 13% of their weight in study
- Drugmaker’s market value passes $600 billion with latest gain
This article is for subscribers only.
Novo Nordisk A/S touted the potential of its next-generation obesity treatments, releasing promising data on an experimental daily pill and sending the shares soaring to a record.
A new treatment called amycretin, which targets two modes of action against obesity including GLP-1, like the blockbuster injection Wegovy, helped patients shed 13% of their weight over 12 weeks in an early-stage test. The early-stage results suggest the pill may be even more effective than Novo’s Wegovy injection.